engage checkpoint medical linkedin twitter

Early Treatment Intensification for mCSPC: Optimising Patient Selection and Treatment

Early Treatment Intensification for mCSPC: Optimising Patient Selection and Treatment

On-demand video and slides now available

On-demand video and slides now available

Prof. Evan Yu

In this video, expert Prof. Evan Yu shares an update on the evolved treatment landscape for metastatic castration-sensitive prostate cancer. He discusses traditional therapy agents and the emergence of triplet therapy, reviews several key trials, and gives his perspective on using the latest trial data to select appropriate treatments.


Clinical takeaways:

  • Androgen deprivation therapy (ADT) alone is no longer sufficient treatment for mCSPC patients
  • Treatment intensification with either doublet or triplet therapy should occur
  • Patients with de novo, high-volume disease who are fit for chemotherapy should be considered for triplet therapy with ADT + docetaxel + novel hormonal agents (NHA)
  • Patients who are unfit for chemotherapy or have low-volume disease should be considered for doublet therapy with ADT + NHA
Portrait of Evan Yu
Prof. Evan Yu

Medical Oncologist

University of Washington and Seattle Cancer Care Alliance

United States (US)

preview next

Early Treatment Intensification for mCSPC: Optimising Patient Selection and Treatment

time | open 5 min | Dec 2022

I agree that this educational programme:

Early Treatment Intensification for Metastatic Castration Sensitive Prostate Cancer:
Optimising Patient Selection and Treatment

Hello, my name's Evan Yu, I'm a professor of Medicine and Oncology at the University of Washington and Fred Hutchinson Cancer Center in Seattle. Today I'll be talking to you about early treatment intensification for metastatic castration-sensitive prostate cancer, optimising patient selection and treatment.


Let's rewind the clock and recognise that patients with metastatic prostate cancer, that the hallmark of treatment is androgen deprivation therapy. However, as recently as about seven years ago, we started recognising that treatment intensification with agents like docetaxel, with novel hormonal therapy agents, that these lead to dramatic survival benefit. With docetaxel, that benefit may be amplified in those patients that have high-volume disease and with novel hormonal therapy agents there are regulatory approvals for abiraterone, enzalutamide and apalutamide already.


The newest data, however, is looking at triple combination therapy, and the first study in that situation was the ENZAMET study. This looked at patients with androgen deprivation therapy, plus or minus enzalutamide, and they allowed docetaxel as dealer's choice. What ended up happening is about 40% of patients had docetaxel added. And what we saw is significant survival benefit with enzalutamide, which we've seen in other studies. The interesting part of the study was the patient population, about 40% that received androgen deprivation therapy and docetaxel plus minus enzalutamide. And unfortunately, there was not a survival benefit from that population. That being said and done, this was a dealer's choice study, so there may be selection bias at play there in that cohort of the ENZAMET study.


The next study that we saw recently was the PEACE-1 study design, which really had four different arms, meant to ask two different questions. For patients with de novo, so synchronous metastatic disease on presentation, for these patients, is there benefit to adding abiraterone which we saw in the STAMPEDE study and saw in LATITUDE. And also, is there a survival benefit to radiation in the prostate, which that has yet to read out? Of course, we saw survival benefit with abiraterone, but what was most interesting were the patient populations that had abiraterone, androgen deprivation, therapy and docetaxel. So there was a large number of patients who received that triple combination, and compared to just androgen deprivation therapy and docetaxel, there was a significant survival benefit there. So again, some significant data there supporting the concept of triple combination therapy.

Next, we saw the ARASENS study, which is the most recent study. This study did not mandate that patients had de novo metastases, but 86% of the patients did have de novo metastases in the study. So it ended up being a rather aggressive population or cohort of patients. They were randomised, everyone to androgen deprivation therapy and docetaxel versus androgen deprivation therapy, docetaxel and darolutamide. And what we saw in this study was a very dramatic survival benefit, very statistically significant, and keep in mind the 14% of patients that were recurrent disease, that were not de novo presentation. The hazard ratio was still 0.61 because it was a smaller subset of patients, we see a wider confidence interval on the top end did barely cross 1, it was 1.05. But again, that's very provocative data, is yet unanswered whether these patients would receive benefit, but the key eligibility in this study was just fit for docetaxel. But that's why what we're seeing is, fit for docetaxel. But most of the patients were selected out to have rather aggressive features, that's why 86% of the patients had de novo disease. As far as adverse events, mostly docetaxel side effects, not a lot of additional adverse events with darolutamide other than hypertension and rash.


And so I would take in summary, the key take-home point is that patients with metastatic hormone-sensitive prostate cancer, metastatic castration-sensitive prostate cancer, they deserve some sort of treatment intensification, whether it's just a novel hormonal therapy agent or whether it's triple combination therapy. Those with more aggressive features, certainly those with de novo metastases in high-volume disease, I would give them androgen deprivation therapy and docetaxel with either abiraterone or darolutamide. In regards to selection of novel hormonal therapy agents, really look at patient comorbidities, different side effects of the different novel hormonal therapy agents and drug-drug interactions should be considered. The two patient populations I want to see post hoc information on are for those patients that have recurrent disease that is now high-volume and for that patient population that has de novo disease that is low volume, and I'd love to see more data on that.


So on behalf of GU CONNECT, I'd like to wrap up. Thank you very much for your attention. Please refer to the website if you'd like to download slides with more information and details. Have a great day.

This educational programme is supported by an Independent Medical Education Grant from Bayer

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest

preview next